Abstract
The transdermal delivery of opioids offers significant advantages for the management of chronic pain. Transdermal delivery avoids first pass effects, allows sustained drug administration for improved analgesia with reduced breakthrough pain, reduces peak-related side effects and improves patient compliance through reduced dosing frequency. Oxymorphone was selected for clinical development because of its high potency and low oral bioavailability; characteristics ideal for transdermal delivery. We have previously demonstrated in humans that oxymorphone could be delivered from a transdermal matrix patch when formulated with a transdermal penetration enhancer called TPM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
